drug
Xalatan
Marketedupdated 3mo agoby Greenstone LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval12 co-mentions · 6 sources
- drugLATANOPROST8 co-mentions · 8 sources
- druglatanoprost SR8 co-mentions · 8 sources
- companyEpic Pharma LLC5 co-mentions · 5 sources
- drug(clascoterone + latanoprost)1 co-mentions · 1 sources
- drugCB-03111 co-mentions · 1 sources
- companyGlenmark Pharmaceuticals Ltd1 co-mentions · 1 sources
- companyMankind Pharma Ltd1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 3 investigational indications.
all catalysts(6)
approval · 6
Jul 19, 2011
approval
LATANOPROST — FDA approval
Xalatan
→
Sep 22, 2014
approval
LATANOPROST — FDA approval
Xalatan
→
Dec 17, 2025
approval
LATANOPROST — FDA approval
Xalatan
→
Jan 30, 2026
approval
LATANOPROST — FDA approval
Xalatan
→
Jan 30, 2026
approval
LATANOPROST — FDA approval
Xalatan
→
Jan 30, 2026
approval
LATANOPROST — FDA approval
Xalatan
→
Trials studying Xalatan
- phase3Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
- phase3Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
- phase424-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
- phase4Rocklatan vs Latanoprost Post-DSLT
- phase1Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma
- phase2Next Generation Rocklatan
- phase3MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- phase3Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 15, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Jul 8, 2031formulationUS 86370544.9y
- Sep 12, 2029formulationUS 96298523.1y
- Oct 15, 2028method-of-use (U-2400)US 95392622.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that